Antibiotic Resistance
Antibiotic Resistance

Understanding and Responding to an Emerging Crisis

Karl Drlica
David S. Perlin
We thank our families for their support and dedicate this work to the patients and clinicians who are confronting the harsh reality of drug-resistant infections.
This page intentionally left blank
# Contents

About the Authors ........................................ xiii

Preface .................................................. xv

## Chapter 1  Introduction to the Resistance Problem ........................................ 1

MRSA Is Putting Resistance in the News .................. 1
Humans Live with Many Pathogens .................... 4
Antibiotics Block Growth and Kill Pathogens .......... 6
Broad-Spectrum Antibiotics Also Perturb Our Microbiomes ........................................ 7
Antibiotic Resistance Protects Pathogens ............... 8
Antibiotic Resistance Is Widespread .................. 9
Antibiotic Resistance Is Divided into Three Types ..... 12
The Development of New Antibiotics Is Slowing ........ 12
Vaccines Block Disease .................................. 13
Perspective ................................................ 14

## Chapter 2  Working with Pathogens ........................................ 17

Pathogens Are a Diverse Group of Life Forms .......... 17
Pathogen Numbers Are Measured by Microscopy and by Detecting Growth .................. 18
Molecular Probes Can Be Specific and Highly Sensitive .... 23
Koch’s Postulates Help Establish That a Pathogen Causes Disease ............................... 24
Modern Biology Has Refined Koch’s Postulates .......... 26
Pathogen Studies Focus on Populations .................. 28
Perspective ................................................ 29

## Chapter 3  A Survey of Antibiotics ........................................ 31

Antibiotics Are Selective Poisons ......................... 31
Antibiotics Are Found in a Variety of Ways .............. 32
Antibacterial Agents Usually Attack Specific Targets .... 37
Antibacterial Agents May Have a Generalized Effect .... 40
Most Antifungal Agents Attack Membranes and Cell Walls ........................................ 41
Antiprotozoan Agents Tend to Be Disease-Specific ..... 43
Antihelminth Agents Are Used with a Variety of Worms ........................................ 45
Antiviral Agents Are Often Narrow Spectrum ........................................ 45
Human Immunodeficiency Virus (HIV) ........................................ 46
Influenza Virus ...................................................... 48
Herpes Virus ...................................................... 49
Antibiotic Classes Evolve ........................................ 50
Antiseptics and Disinfectants Decontaminate Surfaces ............. 52
Perspective .......................................................... 53

Chapter 4  Dosing to Cure ........................................ 55
Treatment Strategies Have Been Determined Empirically ............. 55
Susceptibility Testing Guides Antibiotic Choice ................. 57
Testing for Viruses Bypasses Pathogen Growth ................. 62
PK/PD Indices Help Determine Antibiotic Dosage ........... 62
Young Children Are Not Little Adults ......................... 65
Toxic Side Effects Are Determined Empirically ................. 66
Duration of Treatment Is Determined Empirically ............. 67
Prophylaxis Preempts Disease .................................. 67
Management Programs Control Hospital Antibiotic Policy .......... 68
Self-Medication Is Outside the Guidelines ...................... 69
Perspective .......................................................... 70

Chapter 5  Emergence of Resistance ........................................ 73
Resistance Can Emerge in Individual Patients .................... 73
Spontaneous Mutations Are Nucleotide Sequence Changes ........ 74
Emergence of Spontaneous Resistance Often Arises Stepwise .......... 75
Mutant Selection Window Hypothesis Describes Emergence of Spontaneous Resistance ........ 77
Mutations Can Be Caused (Induced) by Antibiotic Treatment .......... 79
Resistance Arises from Several Molecular Mechanisms ........ 80
Treatment Time Can Contribute to Resistance ................ 82
Mutator Mutations Increase Mutation Frequency ........... 83
Phenotypic Resistance Occurs Without Mutations .......................... 84
Resistance May Compromise Antiseptic and Disinfectant Use .................. 84
Viral Resistance Can Arise Readily ........................................... 84
Resistance Mutations Can Affect Pathogen Fitness .............................. 86
Unintended Damage Can Arise from Treatment .................................. 87
Perspective ................................................................................. 89

Chapter 6 Movement of Resistance Genes Among Pathogens ................. 91
Horizontal Gene Transfer Involves Specific Molecular Events ...................... 91
Recombination Involves Breaking and Rejoining of DNA Molecules ................ 92
Plasmids Are Molecular Parasites ................................................. 94
Some Plasmids Move by Conjugation ............................................. 95
Bacteriophages Move Bacterial Genes by Transduction ........................... 96
Bacterial Transformation Involves Uptake of DNA from the Environment ........ 98
Transposition Moves Genes from One DNA to Another .......................... 99
Gene Mobilization Moves Genes from the Chromosome to a Plasmid ............ 99
Integrons Gather Genes into an Expression Site .................................... 101
Genomic Islands Help Create Pathogens .......................................... 102
Plasmid Enzymes Can Be Inhibited ................................................. 103
Perspective ................................................................................. 103

Chapter 7 Transmission of Resistant Disease ...................................... 105
Spread of Pathogens Is Highly Evolved ............................................. 105
Infection Control as Local Crisis Management ..................................... 106
Tuberculosis Is Airborne ................................................................. 107
Airborne Viruses .......................................................................... 114
Digestive-Tract Pathogens .................................................................. 115
Direct-Contact Pathogens .................................................................. 116
Arthropod-Borne Pathogens ............................................................. 118
Blood-Borne Infections ..................................................................... 121
Multiple-Mode Transmission ................................................................ 121
Perspective ................................................................................. 123
Chapter 8  Surveillance ..................................................... 125
Surveillance Is the First Line of Defense ................. 125
The Denominator Effect Lowers Surveillance Accuracy . 126
Surveillance Consortia Collect and Process Data ........ 127
Molecular Methods Provide Rapid Pathogen Identification .................................................. 128
Interpretation of Surveillance Studies .................... 132
Surveillance Indicates Resistance Problems with Gonorrhea ....................................... 133
Policy Changes Are Occurring in Agricultural Practice .................................................. 133
Perspective ................................................................. 137

Chapter 9  Making New Antibiotics ......................... 139
New Antibiotics Are Temporary Solutions ............ 139
Model Systems Are Used to Speed Drug Discovery 140
Natural Products Are a Source of Antibiotics ........ 141
High-Throughput Screening Accelerates Antibiotic Discovery ........................................ 143
Rational Drug Design Can Identify Antibiotics .......... 144
New Antibiotics Must Have Few Side Effects ........ 145
Antibiotic Discovery Faces a Fundamental Economic Problem ...................................... 146
Perspective ................................................................. 147

Chapter 10 Restricting Antibiotic Use and Optimizing Dosing ........................................ 149
Antibiotic Conservation: Use Less Often When Unnecessary and Higher Amounts When Needed 149
Human Consumption of Antibiotics Correlates with Resistance ........................................ 150
Limiting Human Consumption of Antibiotics .......... 152
Agricultural Use Contributes to Antibiotic Consumption ................................................... 155
Antibiotic Contamination of the Environment Is a Byproduct of Usage ......................... 155
Clinical Resistance and Resistant Mutants Are Not the Same ........................................ 157
Dosing to Eradicate Susceptible Cells May Not Halt Emergence of Resistance .................. 158
Keeping Concentrations Above MPC Restricts Mutant Amplification .......................... 159
Combining MPC with PK/PD Targets .................. 160
Combination Therapy Restricts Emergence of Resistance .......................... 162
Consideration of Resistance During Drug Discovery .................. 163
Perspective .................................................. 164
Chapter 11  Influenza and Antibiotic Resistance ............ 167
Seasonal Influenza Virus Is Controlled by Vaccines ........... 167
Antiviral Resistance Has Emerged Among Seasonal Influenza Virus .................. 168
Pandemic Influenza Can Be a Killer .................. 170
Avian Flu H5N1 Is a Candidate for Deadly Pandemic Flu ........................................ 171
Antibiotics May Play an Important Role in Pandemic Influenza .................................. 172
Antibiotic Resistance Occurs with Avian Flu H5N1 ............. 173
Bacterial Pneumonia May Create Another Resistance Problem ........................................ 175
Perspective .................................................. 176
Chapter 12  Avoiding Resistant Pathogens ............... 177
Consumer Perspective Differs from That of Public Health Official or Manufacturer ........ 177
Avoiding Airborne Infection Is Difficult .................. 178
Precautions Can Be Taken with MRSA .................. 182
Sexually Transmitted Infections Require Renewed Attention ........................................ 185
Arthropod-Borne Infections Are on the Move .................. 186
Contaminated Food Is Common .................. 188
Avoid Rounds of Treatment Interspersed with Pathogen Outgrowth .................. 196
Consume Only with Sound Indications, Choose Optimal Antibiotics .................. 197
Perspective .................................................. 199
About the Authors

Karl Drlica, Ph.D. is a Principal Investigator at the Public Health Research Institute and Professor of Microbiology & Molecular Genetics at the UMDNJ—New Jersey Medical School in Newark, New Jersey. Dr. Drlica’s laboratory focuses on fluoroquinolone action and resistance with Mycobacterium tuberculosis and other bacteria, including approaches for slowing the enrichment and amplification of resistant bacterial sub-populations.

David S. Perlin, Ph.D. is Executive Director of the Public Health Research Institute and UMDNJ Regional Biocontainment Laboratory, as well as Professor of Microbiology & Molecular Genetics at the New Jersey Medical School in Newark, New Jersey. He is also a Fellow of the New York Academy of Sciences. Dr. Perlin’s laboratory explores mechanisms of antifungal drug resistance, rapid detection of drug-resistant bloodstream pathogens in high-risk patients, and the application of small-animal models for the study of respiratory pathogens.
This page intentionally left blank
Recent human activities have profoundly influenced our global environment, often in ways we did not anticipate. An example is our use of antibiotics. Initially hailed as “magic bullets,” these chemical agents are now used so often that success threatens their long-term utility. Unfortunately, the natural mutability of microbes enables pathogens to develop bullet-proof shields that make antibiotic treatments increasingly ineffective. Our failure to adequately address resistance problems may ultimately push the control of infectious disease back to the pre-penicillin era. Indeed, it is now impractical to simply invent additional antibiotics to replace those lost to resistance. However, ideas have emerged for slowing the development of antibiotic resistance in individual patients and in the human population as a whole. *Antibiotic Resistance* introduces these ideas.

*Antibiotic Resistance* was initially drafted to supplement studies of infectious disease. The problem of resistance tends to be neglected, which puts the well-being of our society at increasing peril. In the course of completing this book, we realized that everyone makes decisions about antibiotic use; therefore, everyone needs to understand how human activities contribute to resistance. Individual patients, medical providers, and agricultural specialists all have a role to play in providing a safer environment. We now aim to make the principles of antibiotic use and effectiveness available to a large audience: farmers, hospital administrators, government regulators, health department personnel, pharmaceutical executives, and especially individual users. (Individual patients pressure their doctors for treatments, and in most cases, patients decide whether to take medicines as prescribed; in countries where prescriptions are not required to purchase antibiotics, patients are major decision makers.) Such diversity in readership poses a challenge.

Fortunately, detailed descriptions of chemical structures, molecular mechanisms, and epidemiological modeling are not required to understand the principles of resistance. We focus on broad concepts supported by examples and descriptions of key experiments. We expect that *Antibiotic Resistance* will be a quick read for persons with knowledge of biology. Those readers can then build on the principles with follow-up reading. Lay readers may find that some terms need to be defined. For them, we have provided a glossary and appendices covering background concepts.
Our goal with *Antibiotic Resistance* is to point out how human activities contribute to the problem of resistance. Our hope is that an understanding of the complex factors involved in resistance will lead to changes that lengthen antibiotic life spans. An example of the complexity is seen in the traditional practice of setting antibiotic doses only high enough to cure disease. We argue that this practice encourages the emergence of resistance, that more stringent antibiotic regimens are needed to preempt the emergence of resistance. But from an individual patient perspective, using higher doses seems excessive when milder treatment usually cures disease. Why should the individual patient risk toxic side effects to preserve antibiotics for the general population?

Antibiotic waste disposal problems are also complex. In principle, environmental contamination with antibiotics exerts selective pressure on microbes. That pressure can lead to the evolution of resistance genes that then spread from one organism to another and eventually reach human pathogens. We do not know how often this scenario occurs, whether it is reversible, or how much we need to improve agricultural and hospital disposal programs to stop the process.

Fortunately, many resistance issues are not complex. For example, wearing contaminated gloves can spread drug-resistant disease in hospitals: More attention to hand hygiene is required. We are confident that an improved understanding of antibiotic resistance can help preserve these valuable agents.

Each year, thousands of scientific papers are published on antibiotic resistance, making it difficult for even a pair of authors to get everything right. To improve accuracy, we obtained help from David Alland, Vivian Bellofatto, Arnold Bendich, Purnima Bhanot, John Bradley, Dorothy Fallows, Alexander Firsov, Patrick Fitzgerald, Marila Gennaro, Tao Hong, Dairmaid Hughes, Robert Kerns, Barry Kreiswirth, Shajo Kunnath, David Lukac, Simon Lynch, Muhammad Malik, Barun Mathema, Ellen Murphy, Christina Ohnsman, Richard Pine, Lynn Ripley, Snezna Rogelj, Bo Shopsin, Ilene Wagner, Heinz-Georg Wetstein, Xilin Zhao, and Stephen Zinner. We sincerely thank them for their time and for sharing their knowledge.
Chapter 1

Introduction to the Resistance Problem

Summary: As a normal part of life, we are all exposed to pathogens, the tiny microbes and viruses that cause infectious disease. Many pathogen varieties exist. Some are even harmless inhabitants of our bodies most of the time. A common feature of pathogens is their microscopic size. Another is the huge numbers their populations can reach during infection, often in the millions and billions. Human bodies have natural defense systems, but those systems sometimes fail to control infection. For such occasions, pharmaceutical companies have developed antibiotics, chemicals that interfere with specific life processes of pathogens. As a natural response, antibiotic resistance emerges in pathogen populations. Resistance is a condition in which the antibiotic fails to harm the pathogen enough to cure disease. Emergence of resistance often begins with a large pathogen population in which a tiny fraction is naturally resistant to the antibiotic, either through spontaneous changes or through the acquisition of resistance genes from other microbes. Antibiotic treatment kills or halts the growth of the major, susceptible portion of the microbial population. That favors growth of resistant mutants. Prolonged, repeated use of a particular antibiotic leads to the bulk of the pathogen population being composed of resistant cells. Subsequent treatment with that antibiotic does little good. If the resistant organisms spread to other persons, the resulting infections are resistant before treatment: Control of such infection requires a different antibiotic. The development of resistance is accelerated by the mutagenic action of some antibiotics, by the movement of resistance genes from one microbial species to another, and by our excessive, inappropriate use of antibiotics. In the past, a successful medical strategy was to develop new, more potent antibiotics. However, the pharmaceutical pipeline to new antibiotics is no longer adequate.

In this chapter, we define terms and provide an overview of antibiotic resistance. One of the key problems is that as a global community we have not considered antibiotics as a resource to be actively protected. Consequently, we use antibiotics in ways that directly lead to resistance. Changing those ways requires an understanding of antibiotic principles. We begin with a brief description of MRSA to illustrate a bacterial-based health problem.

MRSA Is Putting Resistance in the News

MRSA is the acronym for methicillin-resistant Staphylococcus aureus. (Acronyms are usually pronounced letter by letter, as in DNA; scientific names are always italicized; after an initial spelling of the entire name, the first name is often abbreviated by its first letter.) S. aureus is a small, sphere-shaped bacterium (see Figure 1-1) that causes skin boils, life-threatening pneumonia, and almost untreatable bone infections. It often spreads by skin-to-skin contact, shared personal items, and shared surfaces, such as locker-room benches. When the microbe encounters a break in the skin, it grows and releases toxins.
Sixty years ago, *S. aureus* was very susceptible to many antibiotics, including penicillin. Susceptibility disappeared, and the pharmaceutical industry produced increasingly potent antibiotic derivatives. Among these was methicillin, which overcame resistance to penicillin. But in 1960, one year after the introduction of methicillin, MRSA was recovered in the United States. As the resistant bacterium spread through hospitals, surgical procedures and long-term use of catheters became more dangerous. MRSA also caused pneumonia, commonly following influenza, and recently skin infections caused by MRSA captured public attention. In one newspaper account,^2^ pimples on a newborn baby were found to contain MRSA. Antibiotics cleared the infection; however, a month later, the father found boils on his own leg that contained MRSA. Treatment cleared the boils, but they came back. The mother developed mastitis during breast feeding that required a 2-inch incision into her breast to drain the infection. About a year later, an older child developed an MRSA boil on his back. The family is now constantly on alert for MRSA, trying to wash off the bacteria before the microbes find a break in the skin.

Community-associated MRSA has its own acronym (CA-MRSA) to distinguish it from the hospital-associated form (HA-MRSA). Many community-associated *S. aureus* strains are members of a group called USA300, which now accounts for half of the CA-MRSA infections. The strain causes

---

**Figure 1-1** *Staphylococcus aureus*. Scanning electron micrograph of many MRSA cells at a magnification of 9,560 times.

Public Health Image Library # 7821; photo credit, Janice Haney Carr.
necrotizing (flesh-eating) skin infection, pneumonia, and muscle infection. In 2005, MRSA accounted for more than 7 million cases of skin and soft tissue infection seen in outpatient departments of U.S. hospitals. As expected, CA-MRSA strains are moving into hospitals. In a survey of U.S. hospitals taken from 1999 through 2006, the fraction of *S. aureus* that was resistant to methicillin increased 90%, almost entirely from an influx of CA-MRSA.

Although many infections tend to occur in persons having weakened immune systems, MRSA can infect anyone. For example, healthy young adults tend to be susceptible to a lethal combination of influenza and MRSA pneumonia. In Chapter 7, “Transmission of Resistant Disease,” we describe occurrences of CA-MRSA infection among athletes. Fortunately, most of these dangerous CA-MRSA strains are still susceptible to several antibiotics; however, that susceptibility may soon disappear.

HA-MRSA has been a problem in hospitals for years; in many countries, it is getting worse. For example, in the United States, MRSA climbed from 22% of the *S. aureus* infections in 1995 to 63% in 2007 (from 1999 through 2005, it increased 14% per year). From 2000 to 2005, MRSA helped double the number of antibiotic-resistant infections in U.S. hospitals, which reached almost a million per year or 2.5% of hospitalizations. In the United States, more persons now die each year from MRSA (17,000) than from AIDS.

MRSA in hospitals is largely an infection-control problem, that is, control requires keeping the organism from spreading from one patient to another, and if possible, keeping it out of the hospital entirely. Neither is easy. For many years, the Dutch have had an aggressive screening program for incoming patients. They isolate persons who test positive for MRSA and treat them with antibiotics that still work with *S. aureus*. Entire wards of hospitals are closed for cleaning when an MRSA case is found, and colonized healthcare workers are sent home on paid leave until they are cleared of the bacterium. The cost is about half that required to treat MRSA blood-stream infections; consequently, the effort is thought to be cost-effective.

Until recently, many U.S. hospitals took a different approach: MRSA infections were considered part of the cost of doing business. Holland is a small country that can implement specialized care—the United States has a much higher incidence of MRSA. Nevertheless, in 2007, a Pittsburgh hospital reported that it had adopted the Dutch method. The hospital saved almost $1 million per year by screening patients and by insisting on more intensive hand-washing protocols for hospital staff. Other U.S. hospitals are reconsidering their own stance.
Individual consumers will begin to search for hospitals having low MRSA incidence. That search will be easier when hospitals publish their drug-resistant infection statistics. Some states now require reporting of MRSA to health departments; consequently, the numbers are being collected. As an added incentive for MRSA control, some insurance carriers refuse to cover hospital costs when a patient contracts MRSA while there. Hospitals have responded by setting up antibiotic oversight committees to help keep resistance under control.

**Humans Live with Many Pathogens**

MRSA is one type of pathogen, the collective word applied to microbes and viruses that cause disease. (The term microbe includes bacteria, some types of fungi, and protozoans.) Each type of microbe has a distinct lifestyle. Bacteria are single-celled organisms that reproduce by binary fission; each cell grows and then divides to form two new cells. Bacteria cause many of the diseases that make headlines: tuberculosis, flesh-eating disease, and anthrax. Pathogenic fungi include yeasts and molds. Yeasts are single-celled, whereas molds tend to grow as thread-like structures composed of many cells. (Some pathogenic fungi switch between the forms in response to the environment.) Yeasts and molds cause pneumonia, and in immuno-suppressed persons yeasts and molds can cause deadly systemic infections. Pathogenic protozoans, such as the types that cause malaria, are single-celled microbes that are often spread by insect bites. In tropical and subtropical regions, protozoan diseases are among the major killers of humans. Protozoa and helminths (worms) are usually called parasites rather than pathogens due to their larger size. In *Antibiotic Resistance*, we do not distinguish between pathogens and parasites, because antibiotics are used for maladies caused by parasites as well as by pathogens.

Viruses differ qualitatively from the cellular organisms just mentioned. Viruses cannot reproduce outside a host cell. They require the machinery of a living cell to make new parts. Indeed, one could argue that viruses are not alive even though they are composed of the same types of molecules found in microbes, plants, and animals. Another feature of viruses is that they are generally much smaller than microbes: An electron microscope is required to see most virus particles, whereas a light microscope is adequate for microbes.
Many microbes and viruses are found in and on our bodies (see Box 1-1). Some are beneficial; others are harmful. Some pathogens only occasionally cause infectious symptoms. For example, *Mycobacterium tuberculosis* enters a dormant state in most persons it infects, with a minority of infected persons exhibiting symptoms. However, immune deficiency enables *M. tuberculosis* to exit dormancy and cause disease. Other serious diseases arise from microbes, such as the yeast *Candida albicans*, that ordinarily live harmlessly in or on humans. This organism causes vaginitis with healthy women and more serious disease with immune-compromised patients.

Pathogens that normally grow only inside humans often have effective means of transmission. *Mycobacterium tuberculosis* and influenza virus are two that spread through air; *Vibrio cholerae*, the cause of cholera, contaminates drinking water; and many digestive tract pathogens move with contaminated food. (*Salmonella typhi*, the bacterium that causes typhoid fever, is an example.) Many other pathogens are spread by insects and ticks. Among these are the protozoans responsible for sleeping sickness and malaria, the bacteria that cause plague and typhus, and many types of viruses, such as the agent of yellow fever. Avoiding contact with pathogens is exceedingly difficult.

**Box 1-1: Pathogen Diversity**

The scientific literature lists about 1,400 species of human pathogen: 538 bacteria, 317 fungi, 287 helminths, 208 viruses, and 57 protozoa. Over the last 20 years, almost 180 species either increased their incidence in humans or are expected to do so shortly. Only a small number, probably fewer than 100, cause disease only in humans. Almost 60% of human pathogens are zoonotic, that is, they move between humans and other vertebrates. Most of the others are commensals that usually live in or on humans without harm or are environmental organisms, living in water or soil. As we change our behavior and environment, new diseases emerge, largely through a species-jump from animal to human. Because human societies continue to evolve and change their interactions with animals, we are continually faced with new infectious diseases. For example, changes in food production led to the mad cow disease problem, the exotic pet trade led to monkeypox outbreaks, and harvesting bush meat (monkeys, and so on) probably led to infection with a virus that evolved into human immunodeficiency virus (HIV).\(^9,10\)
Antibiotics are drugs, taken orally, intermuscularly, or intravenously, that counter an infection. They include agents such as penicillin, tetracycline, ciprofloxacin, and erythromycin. Common bacterial diseases treated with antibiotics are tuberculosis and gonorrhea. Fungal and protozoan diseases are also treatable, but with agents specific for these organisms. (The biochemistry of fungi and protozoa differs substantially from that of bacterial cells.) Antiviral agents constitute a third set of specialized compounds. In general, little cross-reactivity exists among the categories, that is, agents used for fungi do not cure infections caused by viruses, bacteria, or protozoa. However, the principles underlying action and resistance are the same; consequently, in Antibiotic Resistance we lump all these agents together as antibiotics. Combining all the agents into a single category risks confusion, because the public has been told repeatedly not to use antibiotics for viral diseases. In this instruction, antibiotics are equated to antibacterials, and indeed antibacterials should not be used for viral infections. But the world is changing. We now have many antiviral and antifungal agents that are just as antibiotic as penicillin. The important issue is to identify principles that enable experimental data obtained with one agent to be used for making decisions with another. Such a cross-disciplinary effort is facilitated by having a general term (antibiotic); we use specific terms, such as antibacterial and antiviral, only when we need to distinguish the agents.

In molecular terms, antibiotics are small molecules that interfere with specific life processes of pathogens. Antibiotics generally enter a pathogen, bind to a specific component, and prevent the component from functioning. In cases of lethal antibacterials, treatment leads to formation of toxic reactive oxygen species that contribute to bacterial death. Not all antibiotics kill pathogens. Indeed, many of the older drugs only stop pathogen growth. Nevertheless, they can be quite effective because they give our natural defense systems time to remove the pathogens.

Antibiotics have been called magic bullets and miracle drugs because they quickly cure diseases that might otherwise cause death. When penicillin first became available in the middle of World War II, it gave life to soldiers who were otherwise doomed by infection of minor wounds. Penicillin was so valuable that urine was collected from treated soldiers and processed to recover the drug. Now antibiotics enable many complicated surgeries to be performed without fear of infection. Developments in molecular biology have even enabled pharmaceutical companies to design antibiotics that work against viruses. Among the more striking examples are antibiotics that attack the human immunodeficiency virus (HIV): They reduce the viral load and relieve many symptoms of HIV disease.
Broad-Spectrum Antibiotics Also Perturb Our Microbiomes

Our bodies contain trillions of bacteria that have evolved to live in humans. More than 38,000 different species live in the human digestive tract, and bacteria occupy at least 20 distinct niches on our skin. The microbes carried by each host are collectively called a microbiome. Humans have evolved to take advantage of the bacteria, and the bacteria gain advantage from us. Box 1-2 describes examples relating to obesity and pain. Some bacteria help humans digest food, whereas others protect from particular pathogens. For example,

Box 1-2: Microbiomes Contribute to Obesity and Pain

Although human digestive tracts contain many different types of bacteria, more than 90% of the total is composed of two general types: the Bacteroidetes and the Firmicutes. These bacteria, along with others, extract energy from foods that would otherwise be indigestible. Obese persons have a higher percentage of Firmicutes in their guts than thin persons, and when obese persons lose weight, the percentage of Bacteroidetes increases. The increased fraction of Bacteroidetes appears to be associated with lower harvest of energy from food. A similar difference is observed with genetically obese mice. The obese mice appear to be better able to extract energy from their food, leaving considerably less energy in their feces. When normal, germ-free mice received gut bacteria from obese mice, they put on substantially more body fat than when given bacteria from normal mice, even though food consumption was the same in the two groups. Could gut bacteria contribute to human obesity? Could a shift in microbiome explain why farmers get better growth from cattle fed low levels of antibiotics as “growth promoters”?

Microbiomes may also contribute to sensing some types of pain, as studies with mice indicate. One form derives from inflammation, a complex immune response involving the balance of small molecules called cytokines. Germ-free mice are deficient in the ability to experience a type of inflammatory pain. Introducing bacteria from normal mice into the guts of germ-free animals brought the sensation of pain to normal levels after 3 weeks. Thus, gut bacteria do more than just help mammals digest food.
acid-producing bacteria in the vagina keep yeast populations in check. The complex ecosystem of the digestive tract protects humans from *Clostridium difficile*, the cause of a serious form of diarrhea and bowel inflammation. An unwelcome consequence of antibiotic treatment is the death of much of our microbiome, which can enable resistant pathogen populations to expand.

**Antibiotic Resistance Protects Pathogens**

Antibiotic resistance is the capability of a particular pathogen population to grow in the presence of a given antibiotic when the antibiotic is used according to a specific regimen. Such a long, detailed definition is important for several reasons. First, pathogens differ in their susceptibility to antibiotics; thus, pathogen species are considered individually. Second, resistance to one antibiotic may not affect susceptibility to another. This means that the antibiotics must also be considered separately. Third, dose is determined as a compromise between effectiveness and toxicity; dose can be changed to be more or less effective and more or less dangerous. Consequently, the definition of resistance must consider the treatment regimen.

Control of infection caused by a resistant pathogen requires higher doses or a different antibiotic. If neither requirement can be met, we have only our immune system for protection from lingering disease or even death. Indeed, infectious diseases were the leading cause of death in developed countries before the discovery of antibiotics. (They still account for one-third of all deaths worldwide.)

Antibiotic resistance is a natural consequence of evolution. Microbes, as is true for all living organisms, use DNA molecules to store genetic information. (Some viruses use RNA rather than DNA; both acronyms are defined in Appendix A, “Molecules of Life.”) Evolution occurs through changes in the information stored in DNA. Those changes are called mutations, and an altered organism is called a mutant. Therefore, an antibiotic-resistant mutant is a cell or virus that has acquired a change in its genetic material that causes loss of susceptibility to a given antibiotic or class of antibiotics.

Antibiotic-resistant pathogens need not arise only from spontaneous mutations—bacteria contain mechanisms for moving large pieces of DNA from one cell to another, even from one species to another. This process, called horizontal gene transfer (see Chapter 6, “Movement of Resistance Genes Among Pathogens”), enables resistance to emerge in our normal bacterial flora and move to pathogens. It is part of the reason that excessive antibiotic use and environmental contamination are so dangerous.
A pathogen is considered to be clinically resistant when an approved antibiotic regimen is unlikely to cure disease. We quantify the level of pathogen susceptibility through a laboratory measure called minimal inhibitory concentration (MIC), which is the drug concentration that blocks growth of a pathogen recovered from a patient. (Pathogen samples taken from patients are called isolates.) A pathogen is deemed resistant if the MIC for the drug exceeds a particular value set by a committee of experts. Clinicians call that MIC value an interpretive breakpoint. Infections caused by pathogen isolates having an MIC below the breakpoint for a particular antibiotic are considered treatable; those with an MIC above the breakpoint are much less likely to respond to therapy. The MIC for a given patient isolate, reported by a clinical microbiology laboratory, helps the physician make decisions about which antibiotic to use. For example, if the isolate is resistant to penicillin but susceptible to fluoroquinolones, the physician may choose to prescribe a member of the latter class.

Resistant microbes can spread from one person to another. Consequently, an antibiotic-resistant infection differs qualitatively from a heart attack or stroke that fails to be cured by medicine: Antibiotic resistance moves beyond the affected patient and gradually renders the drug useless, whereas disseminated resistance does not occur with other drugs. Even resistance to anticancer drugs stays with the patient that developed the resistance because cancer does not spread from one person to another. This distinctive feature of antibiotics means that dosing, suitable effectiveness, and acceptable side effects must be decided by different rules than apply for treatment of noncommunicable diseases. The key concept is that using doses that are just good enough to eliminate symptoms may be fine for diseases such as arthritis, but it is an inadequate strategy for infectious diseases. Nevertheless, that strategy has been the norm ever since antibiotics were discovered.

Antibiotic Resistance Is Widespread

The seriousness of antibiotic resistance depends on perspective. For most diseases, we still have at least one effective drug. If we instantly stopped all resistance from increasing, our healthcare system could continue to perform well. But clinical scientists see resistance increasing and call the situation “dire.” For some pathogens, such as MRSA and Acinetobacter, physicians are forced to turn to antibiotics abandoned decades ago due to their toxic side effects. Our collective task is to develop attitudes and policies that enable all of us to use antibiotics without causing resistance to increase.
We estimate the extent of the resistance problem by surveillance studies. As pointed out, physicians collect microbial samples from patients and send the samples to clinical laboratories for testing (more than 2 billion per year in the United States\textsuperscript{14}). Pathogens are cultured, and their susceptibility to specific antibiotics is determined (described in Chapter 2, “Working with Pathogens”). Surveillance workers then collect the data and calculate the percentage of the cultures that are resistant. (MIC breakpoints are used as the criterion for resistance.) This percentage, called the prevalence of resistance, indicates whether a particular antibiotic treatment is likely to fail due to pre-existing resistance. Surveillance also reveals trends when samples are obtained over several years from a similar patient population. Seeing the prevalence of resistance increase gives health planners advance warning that a change in treatment regimen is required.

Often, the prevalence of resistance is low for many years, and then it increases rapidly (see Figure 1-2). The challenge is to identify resistance problems while prevalence is still low. Then public health measures, such as increasing dose or halting the spread of the pathogen, may stop the increase. Many examples exist in which local outbreaks of resistance have been controlled. However, on a global level no antibiotic has returned to heavy use when resistance became widespread. Instead, the antibiotic is replaced with a more potent derivative.

\textbf{Figure 1-2}  Change in prevalence of methicillin resistance in \textit{S. aureus} in Great Britain.

A partial list of major resistance problems is shown in Box 1-3. This list should be considered as a status report that needs to be continually updated, because pathogens are acquiring resistance to more and more antibiotics. It is also important to point out that resistance is generally a local or regional problem. For example, the prevalence of multidrug resistant (MDR) tuberculosis is particularly high in portions of Eastern Europe and South Africa, but in the United States it is rare.

**Box 1-3: Resistance Problems**

Several pathogens are close to becoming difficult to treat with antibiotics in some geographic regions. The pathogens and geographic locations listed in Table 1-1 are examples; a comprehensive listing of problem pathogens would require many pages.

<table>
<thead>
<tr>
<th>Pathogen Species</th>
<th>Disease</th>
<th>Drugs Exhibiting Resistance</th>
<th>Geographical Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Acinetobacter baumanii</em></td>
<td>Pneumonia; wound and urinary infections</td>
<td>All common drugs available; polymyxin is still useful in some localities</td>
<td>Reported worldwide in hospital ICUs(^{15}); pan-resistant in S. Korea, Thailand(^{15,17})</td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em></td>
<td>Pneumonia</td>
<td>Carbapenem, fluoroquinolones, amino glycosides, cephalosporins</td>
<td>Hospitals in many countries, New York City, South Florida(^{18,19})</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em> (XDR-TB)</td>
<td>Tuberculosis</td>
<td>Rifampicin, isoniazid, fluoroquinolone, second-line injectable (kanamycin, amikacin, capreomycin)</td>
<td>Worldwide, particularly Eastern Europe and South Africa(^{20,21})</td>
</tr>
<tr>
<td><em>Neisseria gonorrhoeae</em></td>
<td>Gonorrhea</td>
<td>Penicillins, tetracyclines, fluoroquinolones, macrolides, cephalosporins</td>
<td>Western Pacific, Japan(^{22,23,24})</td>
</tr>
<tr>
<td><em>Salmonella enterica</em></td>
<td>Food-borne bacteremia</td>
<td>Ampicillin, chloramphenicol, tetracycline, sulfamethoxazole, trimethoprim, fluoroquinolones</td>
<td>Worldwide(^{25,28})</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Many types of infection</td>
<td>(\beta)-lactams, fluoroquinolones, gentamycin</td>
<td>Worldwide; examples from European hospitals(^{27,28})</td>
</tr>
</tbody>
</table>
Antibiotic Resistance is Divided into Three Types

Antibiotic resistance is categorized into several types that require different solutions. One is called acquired resistance. As a natural part of life, mutant cells arise either spontaneously (about one in a million cells per generation) or from the transfer of resistance genes from other microbes (see Chapter 6). When a mutant is less susceptible to a particular antibiotic than its parent, mutant growth is favored during treatment. Eventually, the mutant becomes the dominant member of the pathogen population. One way to slow this process is to limit antibiotic use or use doses that block mutant growth.

When the “acquired” mutant starts to spread from person to person, it causes transmitted or disseminated resistance. In this second type of resistance, the pathogen is already resistant before treatment starts. Disseminated resistance is often highly visible and may elicit immediate action by the healthcare community. Much of that action is aimed at halting transmission.

A third type of resistance involves pathogen species unaffected by particular antibiotics. They are said to be intrinsically resistant. Little can be done about this type of resistance except to develop vaccines and use good infection control practices that keep the pathogens away from us. Most viruses fall in this category.

The Development of New Antibiotics Is Slowing

For many years, pharmaceutical companies developed new antibiotics to replace old ones whose effectiveness was seriously reduced by resistance. The new drugs were often more potent versions of earlier compounds. Unfortunately, finding completely new antibiotic classes becomes progressively more difficult as we exhaust the available drug targets in pathogens. Early in the Twenty-First Century, pharmaceutical companies placed considerable hope on genomic technology as a way to find new bacterial drug targets and thereby new antibiotics. In this approach, computer-based analyses examine the information in bacterial DNA and gene expression profiles to identify potential targets for new antibiotics. So far, that approach has not panned out. At the same time, pharmaceutical executives realized that more money could be made from quality-of-life drugs and drugs for managing chronic diseases. For example, heart disease requires life-long therapy to lower cholesterol. In contrast, antibiotics are administered for only short times. Antibiotics also have a large development cost, almost $1 billion per drug. As a result, many major pharmaceutical companies shut down their microbiology divisions. Small biotech companies are taking on the effort, but we can no longer depend on new compounds to postpone the antibiotic resistance problem.
Vaccines Block Disease

Vaccines represent an alternative way to combat microbes and viruses. Vaccines are preparations of attenuated pathogen or noninfectious parts of pathogens. When eaten or injected, vaccines create a protective immune response against a particular pathogen. Some vaccines are so effective that they eliminate a disease, as was the case with smallpox. The absence of disease means no resistance problem. Unfortunately, we have been unable to make effective vaccines for many pathogens, most notably HIV, tuberculosis, and malaria. Moreover, pathogen diversity can generate resistance to a vaccine (see Box 1-4).

Box 1-4: Vaccine-Resistant Pathogens

Vaccines typically instruct the human immune system to recognize a pathogen and destroy it. In some circumstances, the pathogen can alter its surface properties to make it less responsive to the immune system. For example, the malaria parasite frequently changes its surface; consequently, the human immune system is always a step behind the parasite. In other cases, the pathogen species exists in many varieties. Shortly after the U.S. anthrax scare of 2001, considerable concern arose because the bacterial strain used in the attacks, the Ames strain, was relatively resistant to the available vaccines.

Vaccines for Streptococcus pneumoniae (also known as pneumococcus) illustrate the principle of replacement. This organism, which causes pneumonia, otitis media (middle ear infection), sinusitis, and meningitis, colonizes the nasopharynx of 50% of children and about 2.5% of adults. Two types of vaccine are available, one prepared against polysaccharides of 23 pneumococcal strains and the other against a nontoxic diphtheria protein conjugated to polysaccharide from 7 strains of S. pneumoniae. The former reduces the impact of disease, whereas the latter also eliminates colonization by the pathogen. Because more than 90 strains (serotypes) of S. pneumoniae have been identified, neither vaccine was expected to provide full coverage. Nevertheless, the 7-strain vaccine reduced invasive pneumococcal disease by more than 70%. The fraction of antibiotic-resistant pneumococci also dropped. However, elimination of vaccine strains as colonizers created an ecological niche for nonvaccine strains. As a result, serotype 19A, which was rare before the vaccine became available, replaced vaccine strains. In some cases, capsular switching occurred between a vaccine strain (serotype 4) and a nonvaccine strain (serotype 19A) due to genetic recombination. The resulting strains have virulence properties of serotype 4 with low sensitivity to the vaccine (serotype 19A).
Another serious example concerns the pertussis vaccine. Before vaccination began in the 1940s, pertussis (whooping cough) was a major cause of infant death. In the 1990s, pertussis began a resurgence in countries where most of the population had been vaccinated. Some of the resurgence was due to waning vaccine-induced immunity among the elderly, who increasingly were stricken with whooping cough. However, in Holland between 1989 and 2004, a new strain of \textit{Bordetella pertussis}, the causative agent, replaced the old one among children, and the number of whooping cough cases increased. The new strain appears to be more virulent and produces more toxin than the old one.\textsuperscript{30}

\section*{Perspective}

Pathogens have attacked humans throughout history. Before the middle of the twentieth century, we relied on our immune systems to survive those attacks. The unlucky and the weak died. Our immune systems were strengthened by improvements in diet, and the frequency of some pathogen attacks was reduced by sanitation and water purification. For other pathogens, vaccines were developed that further decreased the overall burden of infectious disease. Insecticides provided local protection from being bitten by mosquitoes and other disease-carrying vectors. But our fear of pathogens was eliminated only by antibiotics. By taking pills for a few days, we could quickly recover from most bacterial diseases. Resistance is bringing back our fear of the “bugs.”

Many of our resistance problems derive from the cumulative effects of several complex factors. One has been our cavalier attitude. For example, in early 2009, American supermarket chains began to advertise free antibiotics to attract customers. The underlying message was that antibiotics cannot be very valuable and worth protecting. Another factor is lack of stewardship. Drug resistance is discussed widely among health officials, but a coherent plan has not emerged. Hospitals are beginning to oversee their own use, but agricultural and community antibiotic use is largely uncontrolled after the drugs are approved by governmental agencies. For years, medical scientists, notably Fernando Baquero, Stuart Levy, Richard Novick, and Alexander Tomasz, wrote and spoke passionately about the dangers posed by resistance. The medical community now uses education as a strategy to limit antibiotic use. As a part of this effort, the Centers for Disease Control (CDC) formulate and distribute plans for restricting the emergence of resistance in particular environments. In one survey, neonatal intensive care units failed to adhere to the guidelines about 25\% of the time.\textsuperscript{31} Outside hospitals individual patients continue to insist on
antibacterial treatments for viral infections, a behavior that stimulates the emergence of resistant bacteria and upsets the balance of microbial ecosystems. In the Latino immigrant community, the prescription process is commonly bypassed.\textsuperscript{32,33} Thus, the educational effort needs to be intensified. A third factor is the philosophy behind the choice of dosage. Doses are kept low enough to cause few side effects but high enough to block susceptible cell growth or kill susceptible cells. Conditions that block the growth of susceptible cells but not that of mutants are precisely those used by microbiologists to enrich mutants. Conventional dosing strategies lead \textit{directly} to the emergence of resistance.

Understanding the factors that drive the emergence and dissemination of antibiotic resistance is central to controlling resistance. In the following chapters, we describe how antibiotics are used, how pathogen populations become resistant, and what we as individuals can do about resistance. We begin by considering aspects of pathogen biology relevant to antibiotic treatment.
This page intentionally left blank
Index

A
absolute clinical resistance, 157
Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) properties, 144-145
accuracy of surveillance, denominator effect and, 126-127
Acinetobacter baumannii, 9-11, 205
acquired resistance, 12
acyclovir, 36, 49-50
adamantane resistance, 173-174
adamantane-resistant avian flu virus H5N1, 173
adamantanes, 168
addiction modules, 94-95
adenosine triphosphate (ATP), 36, 219
ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties, 144-145
adverse effects of antibiotics, 200-201
agar, 19
agricultural practice
antibiotics use in, 38, 155, 203-204
removal of fluoroquinolones from U.S. poultry use, 133-134
surveillance in, 135
AIDS, 3, 25-26, 71, 111, 123, 223
airborne infections
avoiding, 178-182
disease transmission, 114
amantadine, 48, 168
aminoglycosides, 34-37, 65, 101-102, 198
amphotericin B, 35, 41, 142
ancient malaria remedies, 44
The Andromeda Strain (Crichton), 114
anthrax outbreak of 2001, 176
antibacterials, 6. See also antibiotics
antibacterial classes and resistance mechanisms, 37-40
generalized effects of, 40-41
antibiotic resistance
antibiotic resistant mutants, 8
definition of, 6-8
three types, 12
antibiotics
adamantanes, 168
adverse effects of, 200-201
antibacterials
antibacterial classes and resistance mechanisms, 37-40
generalized effects of, 40-41
antibiotic classes and resistance mechanisms, 34-36
antifungal classes and resistance mechanisms, 41-43
antihelminth classes and resistance mechanisms, 45
antiprotozoan classes and resistance mechanisms, 43-44
antiviral classes and resistance mechanisms, 45-46
broad-spectrum antibiotics, 7, 32, 56
choosing optimal antibiotics, 197-199
combination therapy, 162-163
discovering new antibiotics, 12, 31-34
computer-assisted drug design, 144-145
consideration of resistance during drug discovery, 163-164
drug safety and side effects, 145-146
economic problems, 146
high-throughput screening, 143-144
model systems for drug research, 140-141
natural sources of antibiotics, 141-142
new antibiotics as temporary solutions, 139
and resistance, 163-164
dosages
antibiotic concentrations above MPC, 159-160
combination therapy, 162-163
combining MPC with PK/PD targets, 160-161
dosing to eradicate susceptible cells, 158-159
environmental contamination with, 155-157
evolution of antibiotic classes, 50-52
how they work, 6, 31-32
lethal compounds, 32
measuring static and lethal action of, 20-21
molecular mechanism of antibiotic action, 32
narrow spectrum, 32
neuraminidase inhibitors, 168-169
overuse of, 14
restricting use of
agricultural use, 155
consideration of resistance during drug discovery, 163-164
environmental contamination by antibiotics, 155-157
human consumption, 150-154
overview, 149-150, 164-165
and risk for subsequent resistance, 200
sales, 203
side effects, 145-146, 200-201
specialized (narrow-spectrum) antibiotics, 32
static compounds, 31
targets, 37-40
protein synthesis, 37-38
DNA replication, 38-39
RNA synthesis, 39
cell wall synthesis, 39
folic acid synthesis, 39-40
antifungal classes and resistance mechanisms, 41-43
antihelminth classes and resistance mechanisms, 45
antimalaria drugs, 43-44, 186-187
antimicrobial streamlining, 106
antimutant strategies for antibiotic development, 164
antiprotozoan classes and resistance mechanisms, 43-44
antiseptics, 52-53, 80, 84, 88, 101, 182
antituberculosis agents, 52, 68, 75, 111-113, 139, 162
antiviral classes and resistance mechanisms, 45-50
ANZCOSS, 59
artemisinin, 43-44, 187
artesunate, 187
arthropod-borne infections
avoiding, 186-187
disease transmission, 118-120
malaria, 223
  ancient malaria remedies, 44
  antibiotic-resistant malaria, 118-119
  antimalaria drugs, 43
  disease transmission, 118-119
  risk in travelers, 186-187
-ase suffix, 208
Asian Flu pandemic (1957-1958), 170
Aspergillus fumigatus, 21, 131, 157
atoms, 207-208
ATP (adenosine triphosphate), 219
AUC (area under the PK curve), 63-65, 71, 160
Australian Society for Antimicrobials, 59
autoclaves, 181
avian flu H5N1, 171-174
avoiding resistant pathogens
  airborne infections, 178-182
  arthropod-borne infections, 186-187
  clashes between personal and public health, 177-179
  food-borne diseases
  Campylobacter, 189, 194-196
disease risks from food-borne pathogens, 188-189
E. coli, 190-194
Salmonella, 190-195
MRSA, 182-184
overview, 177
sexually transmitted infections, 185
avoparcin, 135-136
azidothymidine (AZT), 47
azithromycin, 35, 38, 196
azoles, 35-36, 41-45, 131, 157, 201, 220
AZT (azidothymidine), 47
B
Bacillus anthracis, 140
bacteria
  antibacterials, 6. See also antibiotics
  antibacterial classes and resistance mechanisms, 37-40
generalized effects of, 40-41
biofilms, 29
Bordetella pertussis, 14
Borrelia, 120
Campylobacter, 127, 133-135, 189, 194-196
cellular structure of, 221
Clostridium difficile, 8, 38, 87-89, 123, 200
  colonies, 19
  counting, 19
  culturing, 19-20
  defined, 4-5, 17, 221
digestive-tract pathogens, 115-116
direct-contact pathogens, 116
Escherichia coli, 19, 22, 32, 41, 52, 58, 76, 81-82, 88, 96, 100, 122, 127, 135, 140, 156, 188-195, 198-200
Enterococcus, 102, 115, 135-136
explained, 4
focus on populations, 28-29
Gram-negative, 18, 34, 37-39, 50, 56, 81, 84, 101, 122
Gram-positive, 18, 37-39, 50-52, 81, 101
humans as ecosystems for bacteria, 56
*Klebsiella pneumoniae*, 11, 81, 97, 101, 121-122
lawn, 22
*Mycobacterium tuberculosis*
  completely drug-resistant tuberculosis (CDR-TB), 111
determining antibiotic resistance by genotyping, 130-131
disease transmission, 108-113
dormant state, 5
extensively resistant (XDR) tuberculosis, 11, 111-113
in HIV-positive persons, 111
in homeless populations, 113
latent tuberculosis, 110
multi-drug resistant (MDR), 111-112
testing for exposure to, 109
treatment of, 110-111
vaccination against, 109
persister cells, 28
*Pseudomonas aeruginosa*, 80, 83
quorum sensing, 28
reproduction, 221
ribosomes, 37-38, 43-45, 215-218
rickettsia, 119-120
*S. aureus*, see MRSA
Salmonella, 5, 11, 97, 102, 122, 127, 133, 190-195
SOS response, 79
*Streptococcus pneumoniae*, 13, 175
*Streptomyces*, 39, 81, 141-142, 155
*Vibrio cholerae*, 5
bacterial pneumonia, 175
bactericidal activity, 20-21, 32
bacteriophages, 96-98, 224
  as therapeutics, 97
  integration, 98
lysogenic, 98
bacteriostatic activity, 20-21, 31-32
*Bacteroides*, 38
Bacteroidetes, 7
Baquero, Fernando, 14
ß-lactamase, 35, 41, 81-84, 99, 122, 163
  inhibitors, 81
ß-lactams, 11, 35, 39-41, 65, 74, 81, 99-102, 155, 159, 163, 175, 184, 198-200
biofilms, 29
bleach, 53
blood-borne pathogens, 121
boil, 2
*Borrelia*, 120
bovine spongiform encephalitis (mad cow disease), 26
breakpoint, 9, 125-126
broad-spectrum antibiotics, 7, 32
buds (yeast), 222
C
CA-MRSA (community-associated MRSA), 2-3, 103, 117, 182, 185
*Campylobacter*, 127, 133-134, 189, 194-196
Candida albicans, 5, 18, 41-42, 154, 222

carbapenemase, 122
carbohydrates, 218-219

Carson, Rachel, 187
cassette integration, 92

CC398, 184

CDC (Centers for Disease Control), 14, 127, 179

CDR-TB (completely drug-resistant tuberculosis), 111

Chagas disease, 44

Chain, Ernst, 34

children, treatment strategies for, 65-66

chinchona tree, medicinal properties for malaria, 44

chloramphenicol, 142

chloroquine, 43, 118

Choleraesuis, 195

choosing optimal antibiotics, 197-199

ciprofloxacin, 50, 176

clarithromycin, 38

clashes between personal and public health, 177-179

clavulanic acid, 81

Clinical Laboratory Standards Institute (CLSI), 20, 58

clinical resistance, 9, 157

Clostridium difficile, 38, 87-88

codons, 210

cold viruses, 114

combination therapy, 162-163

combining MPC with PK/PD targets, 160-161

commensals, 5, 56-57, 83, 87, 99-100, 131, 155, 164, 189, 193-194

community-associated MRSA (CA-MRSA), 2-3, 103, 117, 182, 185

completely drug-resistant tuberculosis (CDR-TB), 111

complex-17, 136

Compound 606 (salvorsan), 33

computer-assisted drug design, 144-145

conjugation, 91, 95-96, 103

consumption, 107

contaminated food

Campylobacter, 189, 194-196
disease risks from food-borne pathogens, 188-189

E. coli, 190-194

Salmonella, 190-195

correlation between human consumption of antibiotics and resistance, 150

counting pathogens, 18-23

covalent bonds, 207

Crichton, Michael, 114

Cryptosporidium, 44

culturing bacteria, 19-20

cytochrome P-450 (CYP450) enzyme system, 65

cytokines, 7

D
daptomycin, 35, 39

DDT, 103, 120, 187

DEET, 186
Denmark

ban of use of antibiotics as growth promotors, 155
MRSA initiatives, 205
surveillance in food animals, 135
denominator effect and surveillance accuracy, 126-127
deoxiribonucleic acid. See DNA
digestive-tract pathogens, 115-116
digitalis, 142
dihydropteroate synthetase, 39
direct-contact pathogens, 116
directly observed therapy (DOT), 110
disc diffusion, 57-58
discovering new antibiotics
computer-assisted drug design, 144-145
consideration of resistance during drug discovery, 163-164
drug safety and side effects, 145-146
economic problems, 146
high-throughput screening, 143-144
model systems for drug research, 140-141
natural sources of antibiotics, 141-142
new antibiotics as temporary solutions, 139
disease outbreak response.  
See surveillance
disease transmission. See transmission of resistant disease
disinfectants, 52-53, 80, 84, 121, 194, 199
disseminated resistance, 12
diversity of pathogens, 5, 17-18

DNA (deoxyribonucleic acid)
complementary base pairing, 211
dynamic nature of, 212
explained, 209-213
horizontal gene transfer, 8
integrons, 101-102
mimic, 83
nucleic acid probes, 23-24
plasmids, 91, 94
recombination, 92-93
resistance mutations, 157
  effect on pathogen fitness, 86
  explained, 74-75
  fluoroquinolone-resistant gyrase mutants, 82
  induced mutations, 79-80
  mutant selection window hypothesis, 77-79
  mutator mutations and increased mutation frequency, 83
  stepwise selection of resistance, 75-76
topoisomerases, 38
transposons, 99

Domagk, Gerhard, 31-34
dosing strategies, 15. See also treatment strategies
antibiotic concentrations above MPC, 159-160
changing dosage levels, 204
combination therapy, 162-163
combining MPC with PK/PD targets, 160-161
determining with PK/PD (pharmacokinetics/pharmacodynamics) indices, 62-65
dosing to eradicate susceptible cells, 158-159
DOT (directly observed therapy), 110
drinking water, antibiotic contamination of, 156

drug discovery
computer-assisted drug design, 144-145
consideration of resistance during, 163-164
drug safety and side effects, 145-146
economic problems, 146
high-throughput screening, 143-144
model systems for drug research, 140-141
natural sources of antibiotics, 141-142
new antibiotics as temporary solutions, 139
“druggable” proteins, 145

Duesberg, Peter, 25-26
duration of treatments, 67

E
E-test, 57
E. coli, 19, 22, 32, 41, 52, 58, 76, 81-82, 88, 96, 100, 122, 127, 135, 140, 156, 188-195, 198-200
echinofungins, 42
economic problems with antibiotic discovery, 146
educating about dangers of antibiotic overuse, 203
efflux pumps, 34-35, 64, 75-76, 80, 198-199, 204, 220

Ehrlich, Paul, 31-33
electron microscopy, 4, 18
electrons, 207

EMEA (European Medicines Evaluation Agency), 58

emergence of resistance
antiseptic and disinfectant use, 84
explained, 73
in individual patients, 73-74, 196-197
molecular mechanisms, 80-82
mutations
effect on pathogen fitness, 86
explained, 74-75
fluoroquinolone-resistant gyrase mutants, 82
induced mutations, 79-80
mutant selection window hypothesis, 77-79
mutator mutations and increased mutation frequency, 83
phenotypic resistance, 84
stepwise selection of resistance, 75-76
treatment time and, 82-83
unintended damage arising from treatment, 87-88
viral resistance, 84-86

empiric therapy, 55-56, 60-61, 65-67, 71, 126, 160, 184, 193

Enterococcus, 115
Enterococcus faecalis, 102
global spread of, 136
vancomycin-resistant Enterococcus faecium, 115
environmental contamination by antibiotics, 155-157, 204
enzymes, 208
ergosterol, 35, 41-43
erythromycin, 142, 150
ESBLs (extended-spectrum β-lactamases), 81, 122
estradiol, 223
ethambutol, 110
EUCAST (European Committee for Antimicrobial Susceptibility Testing), 20, 58-59
eukaryotic organisms, 221
European Committee for Antimicrobial Susceptibility Testing (EUCAST), 20, 58-59
European Medicines Evaluation Agency (EMEA), 58
evolution
antibiotic resistance as consequence of, 8
of antibiotic classes, 50-52
extended-spectrum β-lactamases (ESBLs), 81, 122
extensively resistant (XDR) tuberculosis, 11, 61, 111-113, 178-179

F
F plasmid, 96
face masks, 180
Falkow, Stanley, 27
Fermicutes, 7
FFP-2 face mask, 180
Fleming, Alexander, 31-33
flexibility of DNA molecules, 212
Florey, Howard, 33
fluconazole, 41
flucytosine, 42
fluoroquinolone-resistant gyrase mutants, 82
fluoroquinolones, 50, 212. See also quinolones
evolution of, 50-52
fluoroquinolone resistance, 83
fluoroquinolone-resistant gyrase mutants, 82
removal from U.S. poultry use, 133-135
resistance mechanisms, 38
folate, 40
Food and Drug Administration (FDA), 40, 66-68, 179
food animals, 89
food-borne disease, avoiding
Campylobacter, 189, 194-196
disease risks from food-borne pathogens, 188-189
E. coli, 190-194
Salmonella, 190-195
formaldehyde, 53
formularies, 68, 106
foscarnet, 46
France, antibiotic use in, 153
frequency of mutations, 28
fungal diseases, 222-223
fungi
cellular structure of, 222
defined, 4, 17, 222
fungal diseases, 222-223
immune modulators and fungal infections, 42
molds, 222
Paracoccidiodes brasiliensis, 223
structure of, 222
yeasts, 222

G

garenoxacin, 52
gatifloxacin, 52
gemifloxacin, 52
general recombination, 92
generalized effects of antibacterials, 40-41
generalized transduction, 98
genes, 210
gene expression, 216
horizontal gene transfer
  addiction modules, 95
  cassette integration, 92
  conjugation, 91, 95-96
  explained, 91-92
gene mobilization, 99
genomic islands, 102-103
  integrons, 101-102
  plasmids, 94
  recombination, 92-93
  relaxase, 103
  transduction, 91, 96-98
  transformation, 98
  transposition, 92, 99
  vertical transfer, 91
ge genetic recombination, 13, 92-93, 96-102, 212
genomic islands, 102-103
genotyping, 130-131
gentamycin, 38
Germany, antibiotic use in, 153
Giardia, 44
glossary, 227-231
glycosomes, 44
gonorrhea, 11, 52, 133, 185
Gram, Christian, 18
Gram-negative bacteria, 18
Gram-positive bacteria, 18
griseofulvin, 43
growth promotors, use of antibiotics as, 7, 38, 86, 135-136, 155, 165, 203
guinea pig test for tuberculosis, 108
gyrase A protein, 82

H

H1N1 influenza, 169-170
H1N2 influenza, 169
H3N2 influenza, 169
H5N1 avian flu, 171-172
HA-MRSA (hospital-associated MRSA), 2-3, 175, 182
hand hygiene, 123, 181
hand sanitizers, 199
hantavirus pulmonary syndrome, 182
Hata, Sahachiro, 33
helicases, 212
helminths
defined, 4, 17, 224
diseases caused by, 224
herpes virus, 49-50
high-throughput screening, 143-144
Hill, Bradford, 27
Hippocrates, 142

homeless populations, tuberculosis and, 113

homologous recombination, 92

Hong Kong Flu pandemic (1968-1969), 170

horizontal gene transfer, 8

cassette integration, 92

conjugation, 91, 95-96

explained, 91-92

gene mobilization, 99

genomic islands, 102-103

integrons, 101-102

plasmids

  addiction modules, 95

  explained, 94

recombination, 92-93

relaxase, 103

transduction, 91, 96-98

transformation, 98

transposition, 92, 99

hospital antibiotic policy, 68-69, 106

hospital contact, controlling infections spread by, 123

hospital-associated MRSA (HA-MRSA), 2-3, 182

human consumption of antibiotics

correlation with resistance, 150-152

limiting, 152-154

human immunodeficiency virus (HIV), 25, 46-48, 224

hybridization, nucleic acid, 23-24

hydrocarbon, 219

hydrophobic interactions, 219

hydroxyl radicals, 41

hyphae, 18, 21, 222

identifying clinically resistant pathogens, 9

IDSA (Infectious Disease Society of America), 56

immigrant self-medication, 69-70

immune modulators and fungal infections, 42

immunological tests, 62

immune system, 14, 42

immune reconstitution inflammatory syndrome, 67

individual patients, emergence of resistance in, 73-74, 196-197

induced mutations, 79-80

infection control as local crisis management, 3, 106-107

Infectious Disease Society of America (IDSA), 56

influenza

antiviral mechanisms, 168

antiviral resistance, 3, 168-170, 173-175

avian flu H5N1, 171-174

avoiding, 179-181

bacterial pneumonia associated with, 175

membrane protein-2 (M2), 36, 168

overview, 48, 114, 167

pandemic influenza, 170-171

Asian Flu pandemic (1957-1958), 170
management programs to control hospital antibiotic policy

H1N1 pandemic (2009), 170
Hong Kong Flu pandemic (1968-1969), 170

potential role of antivirals, 173

public health strategy, 172, 176

Spanish Flu pandemic (1918–1919), 170

quarantine, 179

vaccination against seasonal influenza virus, 167-168

virus types, 168-169

Inner Canon of the Yellow Emperor, 142

integrase inhibitors, 47

integrons, 36, 101-102, 204-205

interferon-α release assays, 109

interpretation of surveillance studies, 132

intrinsic resistance, 12

iodine, 53

isolates, 60

isoniazid, 52, 110, 162

K

kanamycin, 11, 34, 38, 100

kinetoplasts, 44

Klebsiella pneumoniae, 11, 121-122

Koch’s postulates, 17, 24-28

L

LD (lethal dose), 21

laboratory, biosafety level 3, 23

lead compounds, 143

leishmaniasis, 44

lethal action of antibiotics, measuring, 20-21

lethal compounds, 32

lethal dose (LD), 21

levamisole, 45

levofloxacin, 50-51

Levy, Stuart, 14

LexA, 79

lice, 119-120, 187

light microscopy, 4, 18

lincosamides, 38

linezolid, 34, 37

lipids, 219-220

Listeria, 192

local crisis management, infection control as, 106-107

Lyme disease, 26, 120, 187

lysogenic bacteriophages, 98

lysogeny, 98

M

M. bovis BCG, 140

M. smegmatis, 140

macrolides, 38, 135, 150, 155-156, 185, 198-200

macromolecules, 208

mad cow disease (bovine spongiform encephalitis), 5, 26

malaria, 4, 53, 223

ancient malaria remedies, 44

antibiotic-resistant malaria, 118-119

antimalaria drugs, 43

disease transmission, 118-119

risk in travelers, 186-187

magic bullets, 6

management programs to control hospital antibiotic policy, 68-69
Materia medica, 142
MBC (minimal bactericidal concentration), 21
MDR (multi-drug resistant) tuberculosis, 11, 61, 111-113, 125, 137, 179, 196
measuring
  numbers of pathogens, 18-23
  static and lethal action of antibiotics, 20-21
mebendazole, 45
membrane protein-2 (M2), 168
messenger RNA (mRNA), 37, 216
metabolic pathways, 220
methicillin, 139
methicillin-resistant Staphylococcus aureus. See MRSA
metronidazole, 44
MexAB-OprM, 80
MexCD-OprJ, 80
MexEF-OprN, 80
MexXY-OprM, 80
MfpA, 83
MIC (minimal inhibitory concentration), 9, 20-21, 55-59, 78, 161
  MIC creep, 126
microbes, 4
microbiomes, 7
microscopy, 18
minimal bactericidal concentration (MBC), 21
minimal effective concentration, 21
minimal inhibitory concentration. See MIC
model systems for drug research, 140-141
molds
  Aspergillus fumigatus, 21, 157
cellular structure of, 222
described, 4, 222
spores, 222
molecular beacons, 129-130
molecular mechanism of antibiotic action, 32
molecular probes, 23-24
molecular resistance mechanisms, 80-82
molecules, 207-208
monkeypox, 5, 26
morphine, 142
mosquitos
  transmission of malaria, 118-119
  transmission of West Nile Virus, 120
moxifloxacin, 52, 139
MPC (mutant prevention concentration), 77-79, 97, 158, 164
  antibiotic concentrations above MPC, 159-160
  combining MPC with PK/PD targets, 160-161
MR2 (membrane protein-2), 168
mRNA (messenger RNA), 37, 216
MRSA (methicillin-resistant Staphylococcus aureus), 1-4, 139
  avoiding, 182-184
disease transmission, 117
emergence, 74
European MRSA initiatives, 137, 204
and influenza, 175
susceptibility testing, 60
multi-drug resistant (MDR) tuberculosis, 111-112
multidrug resistant efflux systems, 198
multiple-mode transmission, 121-122
mupirocin, 37
mutant prevention concentration (MPC), 77-78, 160-164
mutant selection window hypothesis, 77-79, 158
mutants, 8
mutations, 8
  effect on pathogen fitness, 86
  explained, 74-75
  fluoroquinolone-resistant gyrA mutants, 82
  frequency of, 28, 75
  induced mutations, 79-80
  mutant selection window hypothesis, 77-79
  mutator mutations and increased mutation frequency, 83
  resistant mutants, 157
  spontaneous mutations, 74-76
  stepwise selection of resistance, 75-76
mutator mutations and increased mutation frequency, 83
Mycobacterium tuberculosis, 5, 11
antituberculosis agents, 52
antituberculosis program in Peru, 61-62
completely drug-resistant tuberculosis (CDR-TB), 111
determining antibiotic resistance by genotyping, 130-131
diagnosis by microscopy, 18
directly observed therapy (DOT), 110
disease transmission, 108-113
extensively resistant (XDR) tuberculosis, 111-113, 178
in HIV-positive persons, 66-67, 111
in homeless populations, 113
latent tuberculosis, 110
model organisms for research, 140
multi-drug resistant (MDR), 111-112, 137
prophylactic isoniazid treatment, 68
slow growth, 60
testing for exposure to, 109
transmission of, 107-114, 178
treatment of, 66-67, 110-111, 139
vaccination against, 109
N
nalidixic acid, 34, 50
narrow-spectrum antibiotics, 32
National Healthcare Safety Network (NHSN), 128
natural sources of antibiotics, 141-142
Neisseria gonorrhoeae, 11, 52, 185
neomycin, 142
neosalvarsan, 33
neuraminidase inhibitors, 168-169
neuraminidases, 49
new classes of antibiotics, producing, 203
NHSN (National Healthcare Safety Network), 128
nonadherence to therapy, 153
norfloxacin, 50
Novick, Richard, 14
nucleic acid-based diagnosis, 128-131
nucleic acid hybridization, 23-24
nucleic acid probes, 23-24
nucleotides
overview, 209-210
pairing between complementary nucleotides, 211
sequence, 29
nystatin, 142

O
obesity, microbiomes and, 7
ofloxacin, 50
oseltamivir (Tamiflu), 49, 168-169, 173, 179
outbreaks of resistance, response to. See surveillance oversight committees, 4
over-the-counter antifungal agents, 154
oxazolidinones, 37

P
pain, microbiomes and, 7
pandemic influenza, 170-171
Asian Flu pandemic (1957-1958), 170
H1N1 pandemic (2009), 170
Hong Kong Flu pandemic (1968-1969), 170
public health strategy, 172, 176
Spanish Flu pandemic (1918–1919), 170
Paracoccidioides brasiliensis, 223
parasites, 4, 224
parasitic worms, 224
paromycin, 44
pathogen fitness, effect of resistance mutations on, 86
pathogens. See also specific pathogens
arthropod-borne pathogens, 118-120
avoiding
airborne infections, 178-182
arthropod-borne infections, 186-187
clashes between personal and public health, 177-179
food-borne diseases, 188-196
MRSA, 182-184
overview, 177
sexually transmitted infections, 185
bacteria. See bacteria
blood-borne pathogens, 121
commensals, 5
defined, 4
detection by nucleic acids, 128-131
digestive-tract pathogens, 115-116
direct-contact pathogens, 116
diversity of, 5, 17-18
establishing causal relationships with disease
Falkow’s corollaries, 27-28
Hill’s corollaries, 27
Koch’s postulates, 24-26
explained, 4, 17
extensively resistant, 11
focus on populations, 28-29
fungi
cellular structure of, 222
defined, 17, 222
fungal diseases, 222-223
immune modulators and fungal infections, 42
molds, 222
Paracoccidioides brasiliensis, 223
structure of, 222
yeasts, 222
helminths
defined, 17, 224
diseases caused by, 224
identifying clinically resistant pathogens, 9
measuring numbers of, 18-23
multiple-mode transmission, 121-122
pathogen diversity, 5
protozoa
defined, 17, 223
diseases caused by, 4, 223-224
transmission of, 5
vaccine-resistant pathogens, 13
viruses. See viruses
zoonotic pathogens, 5
PCR (polymerase chain reaction), 213-215
penicillin, 6, 31-33, 151-152
pentamidine, 44
persisters, 28
personal health, clashes with public health, 177-179
pertussis (whooping cough), 14
Peru, antituberculosis program in, 61-62
pharmacodynamics, 62-65
pharmacokinetics, 55, 62-65
pharmacokinetic mismatch and resistance, 162
phenotypic resistance, 84
phosphonates, 103
pigs, MRSA in, 184
PK/PD (pharmacokinetics/pharmacodynamics) indices, 62-65, 71
combining MPC with PK/PD targets, 160-161
plague, 5
plasms, 91, 94
Plasmodium falciparum, 118
Plasmodium knowlesi, 118
Plasmodium malariae, 118
Plasmodium ovale, 118
Plasmodium vivax, 118
pneumonia, 1-3, 11
bacterial pneumonia, 175
see Klebsiella and Streptococcus pneumoniae
polymerase, 211
polymerase chain reaction (PCR), 213-215
polymerase inhibitors, 47
polymers, 208
populations, focus on, 28-29
poultry, removal of fluoroquinolones from, 133-134
prescriptions, 89
prevalence of antibiotic resistance, 9-11, 125
prokaryotic organisms, 221
Prontosil Red, 34
prophylaxis, 67-68
prophylaxis, 67-68
protective clothing, virus transfer from, 181
protein synthesis, antibacterial action on, 37
proteins
gyrase A, 82
LexA, 79
MfpA, 83
overview, 208-209
repressors, 216
protozoa
defined, 17, 223
diseases caused by, 4, 223-224
*Pseudomonas aeruginosa*, 52, 80, 83, 122-123, 197-198
public health, clashes with personal health, 177-179
puromycin, 142
pyrazinamide, 110
pyrethrum, 187
Q
quarantine for influenza, 179
quaternary ammonium compounds, 53
quinacrine, 43
quinine, 43-44
quinolone (fluoroquinolone), 34, 38-41, 50-52, 82, 100, 134, 139, 159-160, 175
quorum sensing, 28-29
R
reactive oxygen species, 40-41
recombination, 92-93
relaxase, 103
repressors, 216
reproduction
of bacteria, 221
of yeasts, 222
research, importance of, 205
resistance
antiseptic and disinfectant use, 84
and consumption, 150-155
emerging in individuals, 73-74, 196-197
explained, 73
horizontal gene transfer
addiction modules, 95
cassette integration, 92
conjugation, 91, 95-96
explained, 91-92
gene mobilization, 99
genomic islands, 102-103
integrons, 101-102
plasmids, 94
recombination, 92-93
relaxase, 103
transduction, 91, 96-98
transformation, 98
transposition, 92, 99
molecular mechanisms, 80-82
mutations
effect on pathogen fitness, 86
explained, 74-75
fluoroquinolone-resistant gyrase mutants, 82
induced mutations, 79-80
mutant selection window hypothesis, 77-79
Shigella 267

mutator mutations and increased mutation frequency, 83
pathogen fitness, 86
perspective, 177-178
phenotypic resistance, 84
problems, 11, 14-15
stepwise selection of, 75-76
treatment time and, 82-83
unintended damage arising from treatment, 87-88
viral resistance, 84-86
resistant disease transmission. See transmission of resistant disease
resistant pathogens, avoiding
airborne infections, 178-182
arthropod-borne infections, 186-187
clashes between personal and public health, 177-179
food-borne diseases, 188-196
MRSA, 182-184
overview, 177
sexually transmitted infections, 185
response to disease outbreaks. See surveillance
restricting antibiotic use. See also dosing strategies
agricultural use, 155
consideration of resistance during drug discovery, 163-164
environmental contamination by antibiotics, 155-157
human consumption
correlation between human consumption of antibiotics and resistance, 150-152
limiting, 152-154
overview, 149-150, 164-165
ribavirin, 46
ribonucleic acid. See RNA
ribosomes, 37-38, 43-45, 215-218
ricin, 37
rickettsia, 119-120
rifampicin, 39, 52, 110, 162, 216
rifamycin, 142
rimantadine, 168
RNA (ribonucleic acid)
mRNA, 37
overview, 215-218
rRNA, 37
tRNA, 37
Russia, training TB workers in, 112
S
S. aureus, 1-4, 116-117, 139, 158-159, 175. See also MRSA
salicylic acid, 142
Salmonella, 5, 11, 97, 102, 122, 127, 133, 141, 188-195
salvorsan, 33
SARS (severe acute respiratory syndrome), 114-115, 181
seasonal influenza virus
antiviral resistance to, 168-170
vaccination against, 167-168
self-medication, 69-70, 154, 197
serotype, 13
severe acute respiratory syndrome (SARS), 114-115, 181
sexually transmitted infections, avoiding, 185
Shigella, 192
sickle cell disease, 224
sickle-cell trait, 223
side effects of antibiotics, 66-67, 145-146, 200-201
*Silent Spring* (Carson), 187
site-specific recombination, 92
sleeping sickness, 44
solutions for antibiotic resistance
drug discovery process, 204
education, 203
European MRSA initiatives, 204
higher dosage levels, 204
limited agricultural use of antibiotics, 203
lower environmental levels of antibiotics, 204
new classes of antibiotics, 203
research, 205
SOS response, 79
Spanish Flu pandemic (1918–1919), 170
Speaker, Andrew, 178
specialized transduction, 98
spontaneous mutations, 74-75
spores, 17, 222
*Staphylococcus aureus. See S. aureus and MRSA*
static action of antibiotics, measuring, 20-21
static compounds, 31
stepwise selection of resistance, 75-76
Sterling Drug Company, 34
Strategic National Stockpile, 172
*Streptococcus pneumoniae*, 13, 39, 50-52, 76, 159, 164, 177, 180, 201
*Streptomyces*, 39, 81, 141-142
*Streptomyces aureofaciens*, 155
streptomycin, 38, 142
sugars, 218-219
sulbactam, 81
sulfa drugs (sulfonamides), 31, 34, 39-40
surgical masks, 180
surveillance
denominator effect and surveillance accuracy, 126-127
explained, 10, 125
as first line of defense, 125-126
genotyping, 130-131
groups performing surveillance, 127
importance of, 137
interpretation of surveillance studies, 132
nucleic acid-based diagnosis, 128-131
and removal of fluoroquinolones from U.S. poultry use, 133-134
and studies of resistance problems with gonorrhea, 133
surveillance in Danish food animals, 135
surveillance networks for antibiotic resistance, 127-128
susceptibility testing, 57-60
syncytia, 23
T
Tamiflu (oseltamivir), 49, 168-169, 173, 179
tazobactam, 81
TEM enzyme, 81
testing
for *M. tuberculosis* exposure, 109
immunological/biological testing, 62
susceptibility testing, 57-60
tetracycline, 38, 142
*Theory of Febrile Diseases and Synopsis of the Golden Cabinet* (Zhang), 142
ticks, and spread of Lyme disease, 120
tobramycin, 38
tolnaftate, 43
Tomasz, Alexander, 14
topoisomerases, 38, 212
toxic side effects, determining, 66-67, 200
transduction, 91, 96-98
transfer RNA (tRNA), 216-217
transformation, 91, 98
transmission of resistant disease, 5, 105-124
airborne viruses, 114
arthropod-borne pathogens, 118-120
blood-borne pathogens, 121
controlling infections spread by contact in hospitals, 123
digestive-tract pathogens, 115-116
direct-contact pathogens, 116
explained, 105
infection control as local crisis management, 106-107
MRSA, 117
multiple-mode transmission, 121-122
tuberculosis, 108-113
virus transfer from protective clothing, 181
transposition, 92, 99
transposons, 92, 99-101
*Treatise on Differentiation and Treatment of Seasonal Febrile Diseases* (Wu), 142
treatment strategies
children, 65-66
dosing strategies, 15
*antibiotic concentrations above MPC*, 159-160
changing dosage levels, 204
combination therapy, 162-163
combining MPC with PK/PD targets, 160-161
determining with PK/PD (pharmacokinetics/pharmacodynamics) indices, 62-65
dosing to eradicate susceptible cells, 158-159
duration of treatment, 67
immunological therapy, 55-56
management programs to control hospital antibiotic policy, 68-69
overview, 55, 70-71
PK/PD (pharmacokinetics/pharmacodynamics) indices, 62-65
prophylaxis, 67-68
risk for subsequent resistance, 200
self-medication, 69-70
susceptibility testing, 57, 59-60
toxic side effects, determining, 66-67
tuberculosis, 110-111
unintended damage arising from treatment, 87-88
treatment time and emergence of resistance, 82-83
Treponema pallidum, 33
triazoles, 41
trichlosan, 199
tRNA (transfer RNA), 37, 216-217
trovafloxacin, 50
trypanosomes, 44
tuberculosis, 5, 11
  antituberculosis agents, 52
  antituberculosis program in Peru, 61-62
completely drug-resistant tuberculosis (CDR-TB), 111
control program in Peru, 60-62
determining antibiotic resistance by genotyping, 130-131
disease transmission, 108-113
extensively resistant (XDR) tuberculosis, 111, 113
in HIV-positive persons, 111
in homeless populations, 113
latent tuberculosis, 110
model organisms for research, 140
multi-drug resistant (MDR), 11, 111-112
prophylatic isoniazid treatment, 68
testing for exposure to, 109
transmission of, 107-114, 178
treatment of, 110-111
vaccination against, 109
types of antibiotic resistance, 12
typhoid, 5
typhus, 5, 103, 119

U
U.S. poultry, removal of fluoroquinolones from, 133-134
USA-300, 2
unintended damage arising from treatment, 87-88

V
vaccines
  explained, 13
  against seasonal influenza virus, 167-168
  against tuberculosis, 109
  reducing fear of pathogens, 53
  vaccine-resistant pathogens, 13
vaginal yeast infections, 154
valley fever, 223
vancomycin, 39, 142
vancomycin-resistant Enterococcus faecium, 115
vancomycin-resistant enterococci (VRE), 115-116, 135-136
viral focus, 23
viral resistance, 84-86
viral plaques, 22
viruses
  airborne viruses, 114
  antiviral classes and resistance mechanisms, 45-46
  bacteriophage, 22
  cellular structure of, 224
defined, 4, 17, 224
detecting viral antibiotic resistance, 174-175
herpes virus, 49-50
HIV (human immunodeficiency virus), 25, 46-48, 85-86, 224

influenza
  *antiviral resistance to seasonal influenza*, 168-170
  *avian flu H5N1*, 171-174
  *avoiding*, 179-180
  *bacterial pneumonia associated with*, 175
  *membrane protein-2 (M2)*, 168
  *overview*, 48, 114, 167
  *pandemic influenza*, 170-172, 176
  *quarantine*, 179
  *vaccination against seasonal influenza virus*, 167-168

life cycle, 224

SARS (severe acute respiratory syndrome), 114, 181

virus transfer from protective clothing, 181

West Nile Virus, 120

VITEK, 59

VRE (vancomycin-resistant enterococci), 135-136

water, antibiotic contamination of, 156

West Nile Virus, 120, 187

whooping cough, 14

widespread nature of antibiotic resistance, 9-11

World Health Organization, 127

worms (parasitic), 224

Wu Jutong, 142

X

X-ray crystallography, 144

XDR (extensively resistant) tuberculosis, 111-113

Y

yeasts, 17

  *Candida albicans*, 154
  *defined*, 4, 222
  *reproduction*, 222

yellow fever, 5, 53, 118-120

Z

zanamivir, 168

Zhang Zhongjing, 142

zoonotic pathogens, 5